IL1B and HIV-1 infection: While HIV-1 infection establishment was unaffected upon treatment with PR inhibitors (Fig 2D and 2E), both DAR and LOP pretreatment reduced, but did not completely abrogate IL-1β secretion in HIV-1/WT-infected MDMs (Fig 2F), while having a negligible impact on IL-1β secretion in HIV-1/ΔGag-Pol-infected MDMs (Fig 2G, respectively).